MedTrace Logo

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

NCT03411941 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2019-12-05

No results posted yet for this study

Summary

There is a need to investigate the effectiveness of IVT aflibercept injection in routine clinical practice.

The aim of this study is to collect 12-month real-world clinical data from treatment-naïve nAMD patients who started first-line treatment with IVT aflibercept injection, according to the SmPC (Summary of Product Characteristics) and the SERV (Spanish Society of Retina and Vitreous) guidelines. The effectiveness of IVT aflibercept will be assessed by the changes in VA (Visual Acuity) and CRT (Central Retinal Thickness) during treatment.

Conditions

  • Macular Degeneration

Interventions

DRUG

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

IVT(Intravitreal) aflibercept treatment in routine clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-28
Primary Completion
2019-03-01
Completion
2019-03-01

Countries

  • Spain

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03411941 on ClinicalTrials.gov